Hughes syndrome and epilepsy: When to test for antiphospholipid antibodies?

Lupus

Volumn 25, Issue 13, 2016, Pages 1397-1411

  Noureldine, M H A ^a   Harifi, G ^b   Berjawi, A ^a   Haydar, A A ^a   Nader, M ^c   Elnawar, R ^d   Sweid, A ^c   Al Saleh, J ^b   Khamashta, M A ^b,e   Uthman, I ^f  

^a LEBANESE AMERICAN UNIVERSITY   (Lebanon)

^b DUBAI HOSPITAL   (United Arab Emirates)

^c RIZK HOSPITAL   (Lebanon)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e ST THOMAS HOSPITAL   (United Kingdom)

^f AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

anti 2 glycoprotein I; anticardiolipin; Antiphospholipid; convulsion; Epilepsy; Hughes syndrome; lupus anticoagulant; seizure; systemic lupus erythematosus

Indexed keywords

ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PHOSPHOLIPID ANTIBODY;

ANTICOAGULATION; ANTIPHOSPHOLIPID SYNDROME; BRAIN DAMAGE; DISEASE CLASSIFICATION; EPILEPSY; HUMAN; INFORMED CONSENT; LABORATORY TEST; MICROTHROMBUS; NERVE CELL LESION; NEUROIMAGING; NEUROPATHOLOGY; NEUROPSYCHIATRY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEIZURE; TEMPORAL LOBE EPILEPSY; THROMBOCYTOPENIA; WHITE MATTER; COMPLICATION; DIAGNOSTIC IMAGING; DISEASE MANAGEMENT; FEMALE; IMMUNOLOGY; LIVEDO RETICULARIS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; METABOLISM; PROCEDURES;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; DISEASE MANAGEMENT; EPILEPSY; FEMALE; HUMANS; LIVEDO RETICULARIS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MAGNETIC RESONANCE IMAGING; MALE; THROMBOCYTOPENIA; WHITE MATTER;

EID: 84990240213     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203316651747     Document Type: Review

References (114)

1. Vincent A, Bien C, Irani S, Waters P,. Autoantibodies associated with diseases of the CNS: new developments and future challenges. Lancet Neurol 2011; 10: 759-772.
2. Lancaster E, Martinez-Hernandez E, Dalmau J,. Encephalitis and antibodies to synaptic and neuronal cell surface proteins. Neurology 2011; 77: 179-189.
3. McKeon A, Pittock S,. Paraneoplastic encephalomyelopathies: pathology and mechanisms. Acta Neuropathol 2011; 122: 381-400.
4. Blalock J,. The syntax of immune-neuroendocrine communication. Immunol Today 1994; 15: 504-511.
5. De Simoni MG, Imeri L,. Cytokine-neurotransmitter interactions in the brain. Neurosignals 1998; 7: 33-44.
6. Goldstein K, Bhatt R, Barton B, Zalcman S, Rameshwar P, Siegel A,. Effects of hemispheric lateralization and site specificity on immune alterations induced by kindled temporal lobe seizures. Brain Behav Immun 2002; 16: 706-719.
7. Hopkins S, Rothwell N,. Cytokines and the nervous system. I. Expression and recognition. Trends Neurosci 1995; 18: 83-88.
8. Jankowsky J, Patterson P,. The role of cytokines and growth factors in seizures and their sequelae. Prog Neurobiol 2001; 63: 125-149.
9. Kerschensteiner M, Stadelmann C, Dechant G, Wekerle H, Hohlfeld R,. Neurotrophic cross-talk between the nervous and immune systems: implications for neurological diseases. Ann Neurol 2003; 53: 292-304.
10. Rothwell N, Hopkins S,. Cytokines and the nervous system II: Actions and mechanisms of action. Trends Neurosci 1995; 18: 130-136.
11. Yu N, Liu H, Di Q,. Modulation of immunity and the inflammatory response: a new target for treating drug-resistant epilepsy. Curr Neuropharmacol 2013; 11: 114-114.
12. Dobolyi A, Kékesi K, Juhász G, Székely A, Lovas G, Kovács Z,. Receptors of peptides as therapeutic targets in epilepsy research. Curr Med Chem 2014; 21: 764-787.
13. Miyakis S, Lockshin M, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.
14. Merashli M, Noureldine MHA, Uthman I, Khamashta M,. Antiphospholipid syndrome: an update. Eur J Clin Invest 2015; 45: 653-662.
15. Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42: 1309-1311.
16. Uthman I, Noureldine M, Berjawi A, et al. Hughes syndrome and Multiple sclerosis. Lupus 2015; 24: 115-121.
17. Cervera R, Asherson RA, Font J, et al. Chorea in the antiphospholipid syndrome. Clinical, radiologic, and immunologic characteristics of 50 patients from our clinics and the recent literature. Medicine 1997; 76: 203-212.
18. Fisher R, van Emde BW, Blume W, et al. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia 2005; 46: 470-472.
19. Fisher RS, Acevedo C, Arzimanoglou A, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia 2014; 55: 475-482.
20. Inzelberg R, Korczyn A,. Lupus anticoagulant and late onset seizures. Acta Neurol Scand 1989; 79: 114-118.
21. Gibbs J 3rd, Husain A,. Epilepsy associated with lupus anticoagulant. Seizure 2002; 11: 207-209.
22. Lakos G, Kiss E, Regëczy N, et al. Isotype distribution and clinical relevance of anti-beta2-glycoprotein I (beta2-GPI) antibodies: importance of IgA isotype. Clin Exp Immunol 1999; 117: 574-579.
23. Peltola J, Haapala A, Isojärvi J, et al. Antiphospholipid and antinuclear antibodies in patients with epilepsy or new-onset seizure disorders. Am J Med 2000; 109: 712-717.
24. Eriksson K, Peltola J, Keränen T, Haapala A, Koivikko M,. High prevalence of antiphospholipid antibodies in children with epilepsy: a controlled study of 50 cases. Epilepsy Res 2001; 46: 129-137.
25. Yoshimura K, Konishi T, Kotani H, Wakiguchi H, Kurashige T,. Prevalence of positive anticardiolipin antibody in benign infantile convulsion. Brain Dev 2001; 23: 317-320.
26. Debourdeau P, Gerome P, Zammit C, et al. Frequency of anticardiolipin, antinuclear and anti beta2GP1 antibodies is not increased in unselected epileptic patients: a case-control study. Seizure 2004; 13: 205-207.
27. Ranua J, Luoma K, Peltola J, et al. Anticardiolipin and antinuclear antibodies in epilepsy: a population-based cross-sectional study. Epilepsy Res 2004; 58: 13-18.
28. Krause I, Leibovici L, Blank M, Shoenfeld Y,. Clusters of disease manifestations in patients with antiphospholipid syndrome demonstrated by factor analysis. Lupus 2007; 16: 176-180.
29. Constantin T, Kálovics T, Ponyi A, et al. Prevalence of antiphospholipid and antinuclear antibodies in children with epilepsy. Med Sci Monit 2009; 15: CR164-CR169.
30. Liimatainen S, Peltola M, Fallah M, Kharazmi E, Haapala A, Peltola J,. The high prevalence of antiphospholipid antibodies in refractory focal epilepsy is related to recurrent seizures. Eur J Neurol 2009; 16: 134-141.
31. Verrot D, San-Marco M, Dravet C, et al. Prevalence and signification of antinuclear and anticardiolipin antibodies in patients with epilepsy. Am J Med 1997; 103: 33-37.
32. Angelini L, Granata T, Zibordi F, Binelli S, Zorzi G, Besana C,. Partial seizures associated with antiphospholipid antibodies in childhood. Neuropediatrics 1998; 29: 249-253.
33. Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1000 patients. Arthritis Rheum 2002; 46: 1019-1027.
34. Cimaz R, Romeo A, Scarano A, et al. Prevalence of anti-cardiolipin, anti-beta2 glycoprotein I, and anti-prothrombin antibodies in young patients with epilepsy. Epilepsia 2002; 43: 52-59.
35. Sokol D, McIntyre J, Wagenknecht D, et al. Antiphospholipid and glutamic acid decarboxylase antibodies in patients with focal epilepsy. Neurology 2004; 62: 517-518.
36. Shoenfeld Y, Lev S, Blatt I, et al. Features associated with epilepsy in the antiphospholipid syndrome. J Rheumatol 2004; 31: 1344-1348.
37. Cimaz R, Meroni P, Shoenfeld Y,. Epilepsy as part of systemic lupus erythematosus and systemic antiphospholipid syndrome (Hughes syndrome). Lupus 2006; 15: 191-197.
38. Spreafico R, Binelli S, Bruzzone M, Croci D, Rumi V, Angelini L,. Primary antiphospholipid syndrome (PAPS) and isolated partial seizures in adolescence. A case report. Ital J Neurol Sci 1994; 15: 297-301.
39. Appenzeller S, Cendes F, Costallat L,. Epileptic seizures in systemic lupus erythematosus. Neurology 2004; 63: 1808-1812.
40. Herranz M, Rivier G, Khamashta M, Blaser K, Hughes G,. Association between antiphospholipid antibodies and epilepsy in patients with systemic lupus erythematosus. Arthritis Rheum 1994; 37: 568-571.
41. Sanna G, Bertolaccini M, Cuadrado M, et al. Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J Rheumatol 2003; 30: 985-992.
42. Shrivastava A, Dwivedi S, Aggarwal A, Misra R,. Anti-cardiolipin and anti-beta 2 glycoprotein Iantibodies in Indian patients with systemic lupus erythematosus: association with the presence of seizures. Lupus 2001; 10: 45-50.
43. Toubi E, Khamashta M, Panarra A, Hughes G,. Association of antiphospholipid antibodies with central nervous system disease in systemic lupus erythematosus. Am J Med 1995; 99: 397-401.
44. Sanna G, Bertolaccini M, Hughes G,. Hughes syndrome, the antiphospholipid syndrome: a new chapter in neurology. Ann N Y Acad Sci 2005; 1051: 465-486.
45. Arnson Y, Shoenfeld Y, Alon E, Amital H,. The antiphospholipid syndrome as a neurological disease. Semin Arthritis Rheum 2010; 40: 97-108.
46. Silverman I, Restrepo L, Mathews G,. Poststroke seizures. Arch Neurol 2002; 59: 195-201.
47. Leach I, Lennox G, Jaspan T, Lowe J,. Antiphospholipid antibody syndrome presenting with complex partial seizures and transient ischaemic attacks due to widespread small cerebral arterial thrombosis. Neuropathol Appl Neurobiol 1988; 15: 579-584.
48. Postal M, Costallat L, Appenzeller S,. Neuropsychiatric manifestations in systemic lupus erythematosus: epidemiology, pathophysiology and management. CNS Drugs 2011; 25: 721-736.
49. West S,. Neuropsychiatric lupus. Rheum Dis Clin North Am 1994; 20: 129-158.
50. Ward M, Pyun E, Studenski S,. Causes of death in systemic lupus erythematosus. Long-term followup of an inception cohort. Arthritis Rheum 1995; 38: 1492-1499.
51. Andrade R, Alarcón G, González L, et al. Seizures in patients with systemic lupus erythematosus: data from LUMINA, a multiethnic cohort (LUMINA LIV). Ann Rheum Dis 2008; 67: 829-834.
52. Gonzalez-Duarte A, Cantú-Brito CG, Ruano-Calderon L, García-Ramos G,. Clinical description of seizures in patients with systemic lupus erythematosus. Eur Neurol 2008; 59: 320-323.
53. Mikdashi J, Krumholz A, Handwerger B,. Factors at diagnosis predict subsequent occurrence of seizures in systemic lupus erythematosus. Neurology 2005; 64: 2102-2107.
54. Afeltra A, Garzia P, Mitterhofer A, et al. Neuropsychiatric lupus syndromes: relationship with antiphospholipid antibodies. Neurology 2003; 61: 108-110.
55. Formiga F, Mitjavila F, Pac M, Moga I,. Epilepsy and antiphospholipid antibodies in systemic lupus erythematosus patients. Lupus 1997; 6: 486-486.
56. Liou H, Wang C, Chen C, et al. Elevated levels of anticardiolipin antibodies and epilepsy in lupus patients. Lupus 1996; 5: 307-312.
57. Mackworth-Young C, Hughes G,. Epilepsy: an early symptom of systemic lupus erythematosus. J Neurol Neurosurg Psychiatry 1985; 48: 185-185.
58. Hachulla E, Michon-Pasturel U, Leys D, et al. Cerebral magnetic resonance imaging in patients with or without antiphospholipid antibodies. Lupus 1998; 7: 124-131.
59. Honczarenko K, Budzianowska A, Ostanek L,. Neurological syndromes in systemic lupus erythematosus and their association with antiphospholipid syndrome. Neurol Neurochir Pol 2008; 42: 513-517.
60. Hanly JG, Walsh N, Sangalang V,. Brain pathology in systemic lupus erythematosus. J Rheumatol 1992; 19: 732-741.
61. Mihailovi L, Cupi D,. Epileptiform activity evoked by intracerebral injection of anti-brain antibodies. Brain Res 1971; 32: 97-124.
62. Rogers S, Andrews P, Gahring L, et al. Autoantibodies to glutamate receptor GluR3 in Rasmussen's encephalitis. Science 1994; 265: 648-651.
63. He X, Patel M, Whitney K, Janumpalli S, Tenner A, McNamara J,. Glutamate receptor GluR3 antibodies and death of cortical cells. Neuron 1998; 20: 153-163.
64. Karpiak S, Graf L, Rapport M,. Antiserum to brain gangliosides produces recurrent epileptiform activity. Science 1976; 194: 735-737.
65. Liou H-H, Wang C-R, Chou H-C, et al. Anticardiolipin antisera from lupus patients with seizures reduce a GABA receptor-mediated chloride current in snail neurons. Life Sci 1994; 54: 1119-1125.
66. Chapman J, Cohen-Armon M, Shoenfeld Y, Korczyn A,. Antiphospholipid antibodies permeabilize and depolarize brain synaptoneurosomes. Lupus 1999; 8: 127-133.
67. Ziporen L, Shoenfeld Y, Levy Y, Korczyn A,. Neurological dysfunction and hyperactive behavior associated with antiphospholipid antibodies. A mouse model. J Clin Invest 1997; 100: 613-619.
68. Katzav A, Menachem A, Maggio N, Pollak L, Pick CG, Chapman J,. IgG accumulates in inhibitory hippocampal neurons of experimental antiphospholipid syndrome. J Autoimmun 2014; 55: 86-93.
69. Kent M, Vogt E, Rote N,. Monoclonal antiphospholipid antibodies react directly with cat brain. Lupus 1994; 3: 10-10.
70. Fields R, Sibbitt W, Toubbeh H, Bankhurst A,. Neuropsychiatric lupus erythematosus, cerebral infarctions, and anticardiolipin antibodies. Ann Rheum Dis 1990; 49: 114-117.
71. Sabet A, Sibbitt WL, Stidley CA, Danska J, Brooks WM,. Neurometabolite markers of cerebral injury in the antiphospholipid antibody syndrome of systemic lupus erythematosus. Stroke 1998; 29: 2254-2260.
72. Singh S, Gupta M, Ahluwalia J, Singh P, Malhi P,. Neuropsychiatric manifestations and antiphospholipid antibodies in pediatric onset lupus: 14 years of experience from a tertiary center of North India. Rheumatol Int 2009; 29: 1455-1461.
73. Julkunen H, Kaaja R, Jouhikainen T, Teppo A, Friman C,. Malignant hypertension and antiphospholipid antibodies as presenting features of SLE in a young woman using oral contraceptives. Br J Rheumatol 1991; 30: 471-472.
74. Cordeiro M, Lloyd M, Spalton D, Hughes G,. Ischaemic optic neuropathy, transverse myelitis, and epilepsy in an anti-phospholipid positive patient with systemic lupus erythematosus. J Neurol Neurosurg Psychiatry 1994; 57: 1142-1143.
75. Milstone A, Fan A, Fuchs H,. Antiphospholipid syndrome associated with seizures. South Med J 1996; 89: 738-740.
76. Taipa R, Santos E,. Primary antiphospholipid antibody syndrome presenting with encephalopathy, psychosis and seizures. Lupus 2011; 20: 1433-1435.
77. Harel L, Sandborg C, Lee T, von Scheven E,. Neuropsychiatric manifestations in pediatric systemic lupus erythematosus and association with antiphospholipid antibodies. J Rheumatol 2006; 33: 1873-1877.
78. Echaniz-Laguna A, Thiriaux A, Ruolt-Olivesi I, Marescaux C, Hirsch E,. Lupus anticoagulant induced by the combination of valproate and lamotrigine. Epilepsia 1999; 40: 1661-1663.
79. Pardo A, Gonzalez-Porque P, Gobernado J, Jimenez-Escrig A, Lousa M,. Study of antiphospholipid antibodies in patients treated with antiepileptic drugs. Neurologia 2001; 16: 7-10.
80. Krause I, Blank M, Fraser A, et al. The association of thrombocytopenia with systemic manifestations in the antiphospholipid syndrome. Immunobiology 2005; 210: 749-754.
81. Stojanovich L, Kontic M, Djokovic A, et al. Association between systemic non-criteria APS manifestations and antibody type and level: results from the Serbian national cohort study. Clin Exp Rheumatol 2013; 31: 234-242.
82. Francès C, Papo T, Wechsler B, Laporte J-L, Biousse V, Piette J-C,. Sneddon syndrome with or without antiphospholipid antibodies: a comparative study in 46 patients. Medicine 1999; 78: 209-219.
83. Frances C, Piette J-C,. The mystery of Sneddon syndrome: relationship with antiphospholipid syndrome and systemic lupus erythematosus. J Autoimmun 2000; 15: 139-143.
84. Schmidt R, Auer-Grumbach P, Fazekas F, Offenbacher H, Kapeller P,. Anticardiolipin antibodies in normal subjects neuropsychological correlates and MRI findings. Stroke 1995; 26: 749-754.
85. Molad Y, Sidi Y, Gornish M, Lerner M, Pinkhas J, Weinberger A,. Lupus anticoagulant: correlation with magnetic resonance imaging of brain lesions. J Rheumatol 1992; 19: 556-561.
86. Weingarten K, Filippi C, Barbut D, Zimmerman RD,. The neuroimaging features of the cardiolipin antibody syndrome. Clin Imaging 1997; 21: 6-12.
87. Bell CL, Robbins M, Graziano F, Partington C, Turski P, Kornguth S,. Magnetic resonance imaging of central nervous system lesions in patients with lupus erythematosus. Correlation with clinical remission and antineurofilament and anticardiolipin antibody titers. Arthritis Rheum 1991; 34: 432-441.
88. Sarbu N, Alobeidi F, Toledano P, et al. Brain abnormalities in newly diagnosed neuropsychiatric lupus: systematic MRI approach and correlation with clinical and laboratory data in a large multicenter cohort. Autoimmun Rev 2015; 14: 153-159.
89. Wardlaw JM, Smith EE, Biessels GJ, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol 2013; 12: 822-838.
90. Castellino G, Padovan M, Bortoluzzi A, et al. Single photon emission computed tomography and magnetic resonance imaging evaluation in SLE patients with and without neuropsychiatric involvement. Rheumatology 2008; 47: 319-323.
91. Hughes M, Sundgren P, Fan X, et al. Diffusion tensor imaging in patients with acute onset of neuropsychiatric systemic lupus erythematosus: a prospective study of apparent diffusion coefficient, fractional anisotropy values, and eigenvalues in different regions of the brain. Acta Radiol 2007; 48: 213-222.
92. Castillo A, Alonso J, Martínez-Valle F, et al. Increased myo-inositol in parietal white and gray matter as a biomarker of poor prognosis in neuropsychiatric lupus: a case report. Lupus 2014; 23: 1073-1078.
93. Hilker R, Thiel A, Geisen C, Rudolf J,. Cerebral blood flow and glucose metabolism in multi-infarct-dementia related to primary antiphospholipid antibody syndrome. Lupus 2000; 9: 311-316.
94. Schmidt-Wilcke T, Cagnoli P, Wang P, et al. Diminished white matter integrity in patients with systemic lupus erythematosus. Neuroimage Clin 2014; 5: 291-297.
95. Bosma G, Rood M, Huizinga T, De Jong B, Bollen E, Van Buchem M,. Detection of cerebral involvement in patients with active neuropsychiatric systemic lupus erythematosus by the use of volumetric magnetization transfer imaging. Arthritis Rheum 2000; 43: 2428-2436.
96. Zimny A, Szmyrka-Kaczmarek M, Szewczyk P, et al. In vivo evaluation of brain damage in the course of systemic lupus erythematosus using magnetic resonance spectroscopy, perfusion-weighted and diffusion-tensor imaging. Lupus 2014; 23: 10-19.
97. Neligan A, Hauser W, Sander J,. The epidemiology of the epilepsies. Handb Clin Neurol 2012; 107: 113-113.
98. Hart Y, Sander J, Shorvon S, Johnson A,. National General Practice Study of Epilepsy: recurrence after a first seizure. Lancet 1990; 336: 1271-1274.
99. Espinosa G, Cervera R,. Current treatment of antiphospholipid syndrome: lights and shadows. Nat Rev Rheumatol 2015; 11: 586-596.
100. Abreu MM, Danowski A, Wahl DG, et al. The relevance of "non-criteria" clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features. Autoimmun Rev 2015; 14: 401-414.
101. Crowther MA, Ginsberg JS, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003; 349: 1133-1138.
102. Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GR,. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995; 332: 993-997.
103. Levine SR, Brey RL, Tilley BC, et al. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA 2004; 291: 576-584.
104. Brey RL,. Management of the neurological manifestations of APS-what do the trials tell us? Thromb Res 2004; 114: 489-499.
105. Noel N, Dutasta F, Costedoat-Chalumeau N, et al. Safety and efficacy of oral direct inhibitors of thrombin and factor Xa in antiphospholipid syndrome. Autoimmun Rev 2015; 14: 680-685.
106. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891.
107. Arachchillage DJ, Cohen H,. Use of new oral anticoagulants in antiphospholipid syndrome. Curr Rheumatol Rep 2013; 15: 1-9.
108. Pengo V, Banzato A, Bison E, Zoppellaro G, Jose SP, Denas G. Efficacy and safety of rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome: rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trial. Lupus 2015: 0961203315611495.
109. Erkan D, Aguiar C, Andrade D, et al. 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev 2014; 13: 685-696.
110. Petri M,. Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients. Curr Rheumatol Rep 2011; 13: 77-80.
111. Ferrara DE, Liu X, Espinola RG, et al. Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model. Arthritis Rheum 2003; 48: 3272-3279.
112. López-Pedrera C, Ruiz-Limón P, Aguirre MÁ et al. Global effects of fluvastatin on the prothrombotic status of patients with antiphospholipid syndrome. Ann Rheum Dis 2011; 70: 675-682.
113. Erkan D, Vega J, Ramón G, Kozora E, Lockshin MD,. A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome. Arthritis Rheum 2013; 65: 464-471.
114. Sciascia S, Giachino O, Roccatello D,. Prevention of thrombosis relapse in antiphospholipid syndrome patients refractory to conventional therapy using intravenous immunoglobulin. Clin Exp Rheumatol 2012; 30: 409-413.